BDTX
Black Diamond Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.81
+5.23%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -25.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +132.7%
- EBIT
- +125.2%
- Net income
- +132.1%
- EPS
- +130.7%
- Free cash flow
- +147.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026